PGC-1 alpha as modifier of onset age in Huntington disease

被引:86
|
作者
Taherzadeh-Fard, Elahe [1 ]
Saft, Carsten [2 ]
Andrich, Juergen [2 ]
Wieczorek, Stefan [1 ]
Arning, Larissa [1 ]
机构
[1] Ruhr Univ Bochum, Dept Human Genet, D-44780 Bochum, Germany
[2] Ruhr Univ Bochum, St Josef Hosp, Dept Neurol, D-44791 Bochum, Germany
关键词
OF-ONSET; REPEAT LENGTH; GENE; NEURODEGENERATION;
D O I
10.1186/1750-1326-4-10
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Although there is a strong correlation between CAG repeat length and age at onset (AO) of motor symptoms, individual Huntington disease (HD) patients may differ dramatically in onset age and disease manifestations despite similar CAG repeat lengths. This has led to a search for genetic factors that influence AO. In order to identify such a genetic modifier, we analysed polymorphisms in the PGC-1alpha gene. Recent data indicate inhibition of PGC-1alpha function by mutant Htt supporting a link between transcriptional deregulation and mitochondrial dysfunction in HD. In > 400 HD patients, a polymorphism located within intron 2, a potential recombination hot spot, explains a small, but statistically significant, amount of the variability in AO. Our data suggest that PGC-1alpha has modifying effects on the pathogenic process in HD.
引用
收藏
页数:4
相关论文
共 50 条
  • [31] A TEST OF THE HYPOTHESIS THAT AGE AT ONSET IN HUNTINGTON DISEASE IS CONTROLLED BY AN X-LINKED RECESSIVE MODIFIER
    RIDLEY, RM
    FARRER, LA
    FRITH, CD
    CONNEALLY, PM
    AMERICAN JOURNAL OF HUMAN GENETICS, 1992, 50 (03) : 536 - 543
  • [32] PGC-1α and PGC-1β Regulate Mitochondrial Density in Neurons
    Wareski, Przemyslaw
    Vaarmann, Annika
    Choubey, Vinay
    Safiulina, Dzhamilja
    Liiv, Joanna
    Kuum, Malle
    Kaasik, Allen
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2009, 284 (32) : 21379 - 21385
  • [33] The role of PGC-1 alpha in the stabilization of the neuromuscular junction
    Arnold, A. S.
    Christe, M.
    Handschin, C.
    NEUROMUSCULAR DISORDERS, 2011, 21 (9-10) : 746 - 746
  • [34] PGC-1α Rescues Huntington's Disease Proteotoxicity by Preventing Oxidative Stress and Promoting TFEB Function
    Tsunemi, Taiji
    Ashe, Travis D.
    Morrison, Bradley E.
    Soriano, Kathryn R.
    Au, Jonathan
    Roque, Ruben A. Vazquez
    Lazarowski, Eduardo R.
    Damian, Vincent A.
    Masliah, Eliezer
    La Spada, Albert R.
    SCIENCE TRANSLATIONAL MEDICINE, 2012, 4 (142)
  • [35] Hepatic MicroRNA Expression by PGC-1α and PGC-1β in the Mouse
    Piccinin, Elena
    Arconzo, Maria
    Graziano, Giusi
    Vacca, Michele
    Peres, Claudia
    Bellafante, Elena
    Villani, Gaetano
    Moschetta, Antonio
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (22)
  • [36] DEVELOPMENTAL CHANGES IN MCTs AND PGC-1 ALPHA IN THOROUGHBREDS
    Kitaoka, Yu
    Hoshino, Daisuke
    Mukai, Kazutaka
    Hiraga, Atsushi
    Hatta, Hideo
    JOURNAL OF PHYSIOLOGICAL SCIENCES, 2009, 59 : 59 - 59
  • [37] PGC-1 alpha genotype affects PGC-1 alpha mRNA expression and glucose-stimulated secretion in isolated human pancreatic islets
    Del Prato, S
    Ling, C
    Del Guerra, S
    Lupi, R
    Bugliani, M
    Marchetti, P
    Groop, L
    DIABETOLOGIA, 2005, 48 : A102 - A103
  • [38] HUNTINGTON DISEASE IN GEORGIA - AGE AT ONSET
    ADAMS, P
    FALEK, A
    ARNOLD, J
    AMERICAN JOURNAL OF HUMAN GENETICS, 1988, 43 (05) : 695 - 704
  • [39] Activating mitochondrial regulator PGC-1α expression by astrocytic NGF is a therapeutic strategy for Huntington's disease
    Chen, Li-Wen
    Horng, Lin-Yea
    Wu, Chia-Ling
    Sung, Hui-Ching
    Wu, Rong-Tsun
    NEUROPHARMACOLOGY, 2012, 63 (04) : 719 - 732
  • [40] PGC-1 Coactivators in Cardiac Development and Disease
    Rowe, Glenn C.
    Jiang, Aihua
    Arany, Zolt
    CIRCULATION RESEARCH, 2010, 107 (07) : 825 - 838